Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Completed
This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giv... Read More
Gender:
ALL
Ages:
Between 1 year and 29 years
Trial Updated:
03/04/2024
Locations: University of Missouri-Columbia, Columbia, Missouri +2 locations
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Completed
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: HCA Midwest Health/Research Medical Center, Kansas City, Missouri
Conditions: Multiple Myeloma
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Active Not Recruiting
This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri +22 locations
Conditions: Multiple Myeloma in Relapse
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Completed
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Not set, Bridgeton, Missouri +1 locations
Conditions: Multiple Myeloma
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
Completed
This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
Gender:
ALL
Ages:
All
Trial Updated:
06/13/2023
Locations: Silverstein Eye Centers, Kansas City, Missouri
Conditions: Cataract Surgery
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: Columbia Comprehensive, Jefferson City, Missouri +3 locations
Conditions: Multiple Myeloma
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Completed
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: St. Louis Cancer Care, Llp, Bridgeton, Missouri +3 locations
Conditions: Multiple Myeloma
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Completed
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: University of Kansas, Kansas City, Missouri
Conditions: Multiple Myeloma
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Completed
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may fight prostate cancer by lowering the amount of androgens the body makes. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
05/23/2022
Locations: Cancer Institute of Cape Girardeau, LLC, Cape Girardeau, Missouri +7 locations
Conditions: Prostate Cancer
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
Completed
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Tauber Eye Center, Kansas City, Missouri +2 locations
Conditions: Blepharitis
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
Completed
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Silverstein Eye Centers, Kansas City, Missouri
Conditions: Allergic Conjunctivitis
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
Terminated
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2021
Locations: MidAmerica Division, Inc. /ID# 163530, Kansas City, Missouri
Conditions: Small Cell Lung Cancer